We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00578916
First Posted: December 21, 2007
Last Update Posted: July 31, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bristol-Myers Squibb
  Purpose
The purpose of this study is to determine how the human body processes and eliminates the drug (BMS-690514.

Condition Intervention Phase
Cancer Drug: EVRI (BMS-690514) Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetics and Metabolism of [14C] BMS-690514 in Healthy Male Subjects

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Single dose pharmacokinetics of BMS-690514 and radioactivity in plasma and urine [ Time Frame: measured for 10 days post-dose ]

Secondary Outcome Measures:
  • Determination of biotransformation profiles and recorded adverse events [ Time Frame: for 10 days post-dose ]

Enrollment: 17
Study Start Date: January 2008
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: EVRI (BMS-690514)
Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male subjects
  • Body mass index (BMS) of 18 - 30 kg/m², inclusive

Exclusion Criteria:

  • Radiation exposure from diagnostic X-rays (except dental X-rays) in the last year or from clinical trials in the last 5 years
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00578916


Locations
Switzerland
Local Institution
Allschwil, Switzerland, 487 2401
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Study Director, Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00578916     History of Changes
Other Study ID Numbers: CA187-003
First Submitted: December 19, 2007
First Posted: December 21, 2007
Last Update Posted: July 31, 2008
Last Verified: July 2008